NextCure, Inc. Common Stock (NXTC) is a publicly traded Healthcare sector company. As of May 21, 2026, NXTC trades at $9.65 with a market cap of $33.41M and a P/E ratio of -0.49. NXTC moved +0.88% today. Year to date, NXTC is -29.08%; over the trailing twelve months it is +58.09%. Its 52-week range spans $2.69 to $19.20. Analyst consensus is buy with an average price target of $25.00. Rallies surfaces NXTC's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
NextCure Gains FDA Fast Track for Ovarian Cancer ADC, Plans ASCO Data in June: NextCure’s SIM0505 ADC received FDA Fast Track designation for platinum-resistant ovarian cancer and dose optimization has begun, with Phase 1 escalation data slated for ASCO 2026. The company ended Q1 with $29.7 million in cash, sufficient to fund operations through proof-of-concept in the first half of 2027.
| Metric | Value |
|---|---|
| Price | $9.65 |
| Market Cap | $33.41M |
| P/E Ratio | -0.49 |
| EPS | $-19.65 |
| Dividend Yield | 0.00% |
| 52-Week High | $19.20 |
| 52-Week Low | $2.69 |
| Volume | 0 |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-55.84M |
| Gross Margin | 0.00% |
1 analysts cover NXTC: 0 strong buy, 1 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $25.00.